MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, W.
Right arrow Articles by Bertino, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, W.
Right arrow Articles by Bertino, J. R.

Vol. 55, Issue 6, 1088-1093, June 1999

Overexpression of p21waf1 Decreases G2-M Arrest and Apoptosis Induced by Paclitaxel in Human Sarcoma Cells Lacking Both p53 and Functional Rb Protein

WeiWei Li, Jianguo Fan, Debabrata Banerjee, and Joseph R. Bertino

Laboratory of Molecular Pharmacology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York

We examined the effect of overexpression of p21waf1 on cytotoxicity of paclitaxel, a microtubule stabilizer, using a tetracycline-inducible expression system in human sarcoma cells (SaOs-2) that lack both functional retinoblastoma protein and p53. Under normal growth conditions, p21waf1 is not detectable in SaOs-2 cells. Upon p21waf1 induction by tetracycline withdrawal, we observed a reduced apoptotic response to paclitaxel with a 3- to 6-fold increase in IC50 values compared with that of cells not induced by p21waf1. We also observed a 5-fold increase in the IC50 value when cytotoxicity to vincristine, another microtubule-disrupting agent, was assessed, whereas we observed a marked decrease in the IC50 value after p21waf1 induction in response to etoposide, a topoisomerase II inhibitor. After treatment with paclitaxel, less accumulation of G2-M was observed in p21waf1-induced cells compared with non-p21waf1-induced cells (57% versus 74%). p21waf1 induction also inhibited the increased cyclin B1-associated kinase activity induced by paclitaxel. Overexpression of p21waf1 in SaOs-2 cells lacking both p53 and functional retinoblastoma protein may decrease the G2-M arrest induced by paclitaxel due to suppression of the S-G2 checkpoint, resulting in a decreased apoptotic response of cells to paclitaxel.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
P. Blancafort, M. P. Tschan, S. Bergquist, D. Guthy, A. Brachat, D. A. Sheeter, B. E. Torbett, D. Erdmann, and C. F. Barbas III
Modulation of drug resistance by artificial transcription factors
Mol. Cancer Ther., March 1, 2008; 7(3): 688 - 697.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Russo, P. G. Magro, Z. Hu, W.-W. Li, R. Peters, J. Mandola, D. Banerjee, and J. R. Bertino
E2F-1 Overexpression in U2OS Cells Increases Cyclin B1 Levels and cdc2 Kinase Activity and Sensitizes Cells to Antimitotic Agents.
Cancer Res., July 15, 2006; 66(14): 7253 - 7260.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Xu, S. Choudhary, O. Voznesensky, M. Mehrotra, M. Woodard, M. Hansen, H. Herschman, and C. Pilbeam
Overexpression of Cox-2 in Human Osteosarcoma Cells Decreases Proliferation and Increases Apoptosis.
Cancer Res., July 1, 2006; 66(13): 6657 - 6664.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. N. Demidenko, D. Halicka, J. Kunicki, J. A. McCubrey, Z. Darzynkiewicz, and M. V. Blagosklonny
Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel
Cancer Res., May 15, 2005; 65(10): 4401 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-G. Chen, C.-P. H. Yang, M. Cammer, and S. Band Horwitz
Gene Expression and Mitotic Exit Induced by Microtubule-Stabilizing Drugs
Cancer Res., November 15, 2003; 63(22): 7891 - 7899.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. M. Fidler, K. Li, C. Chung, K. Wei, J. A. Ross, M. Gao, and G. D. Rosen
PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy
Mol. Cancer Ther., September 1, 2003; 2(9): 855 - 862.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. L. Gartel and A. L. Tyner
The Role of the Cyclin-dependent Kinase Inhibitor p21 in Apoptosis
Mol. Cancer Ther., June 1, 2002; 1(8): 639 - 649.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. A. Fecteau, J. Mei, and H.-C. R. Wang
Differential Modulation of Signaling Pathways and Apoptosis of ras-Transformed 10T1/2 Cells by the Depsipeptide FR901228
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 890 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. E. Luker, C. M. Pica, R. D. Schreiber, and D. Piwnica-Worms
Overexpression of IRF9 Confers Resistance to Antimicrotubule Agents in Breast Cancer Cells
Cancer Res., September 1, 2001; 61(17): 6540 - 6547.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics